Radiosynthesis of H- and C-labeled Veliparib.

Veliparib, a potent PARP inhibitor used against multiple cancerous cells such as metastatic melanoma, breast, non-small cell lung cancer (NSCLC) and prostatic cancer, is required for absorption, distribution, metabolism and excretion (ADME) and environmental toxicology assessments studies. Tritium-labeled Veliparib was prepared via the tritiodebromination using tritium gas (T ) in two steps. [ C]Veliparib was achieved through an asymmetric synthetic route in seven radioactive steps starting from [ C] (S)-benzyl 2-aminopropanoate.